GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » Preferred Dividends

Tyme Technologies (Tyme Technologies) Preferred Dividends : $0.00 Mil (TTM As of Jun. 2022)


View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Tyme Technologies's preferred dividends for the three months ended in Jun. 2022 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00 Mil.


Tyme Technologies Preferred Dividends Historical Data

The historical data trend for Tyme Technologies's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyme Technologies Preferred Dividends Chart

Tyme Technologies Annual Data
Trend Nov12 Nov13 Nov14 Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Preferred Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tyme Technologies Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Tyme Technologies Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.


Tyme Technologies  (NAS:TYME) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tyme Technologies (Tyme Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921
Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.
Executives
Michael Demurjian director, 10 percent owner, officer: Chief Operating Officer 157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman director, 10 percent owner, officer: CEO and Chief Science Officer 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker director C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl director 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido officer: Chief Financial Officer C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini officer: Corporate Controller 17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry director 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M officer: Acting Chief Medical Officer 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels director 220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman officer: EVP, Product Development 1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor officer: President and CFO 44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin officer: Chief Operating Officer 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

Tyme Technologies (Tyme Technologies) Headlines

From GuruFocus